SCHEMBL1219745

SCHEMBL1219745

CCCCCCC/C=C/CCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCC/C=C/CCCCCCCC

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.86
LPAR1 Q92633 7/20 0.80
LPAR4 Q99677 3/20 0.80
LPAR2 Q9HBW0 3/20 0.80
LPAR3 Q9UBY5 3/20 0.80
ENPP2 Q13822 2/20 0.80
LPAR5 Q9H1C0 2/20 0.80
CES2 O00748 1/20 0.80
LPAR6 P43657 1/20 0.80
TRPV1 Q8NER1 1/20 0.80
FAAH O00519 2/20 0.72
KDM4E B2RXH2 1/20 0.69
DUSP3 P51452 1/20 0.69
MEN1 O00255 1/20 0.69
KMT2A Q03164 1/20 0.69
LMNA P02545 1/20 0.69
PRKCE Q02156 1/20 0.68
PRKCQ Q04759 1/20 0.68
PRKCD Q05655 1/20 0.68
PRKCA P17252 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13848249 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3
SCHEMBL5944443 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3
SCHEMBL2733309 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3
SCHEMBL11782255 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3
SCHEMBL18197507 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3
SCHEMBL1219747 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3
SCHEMBL17099733 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3
SCHEMBL5944442 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3
SCHEMBL16083710 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3
SCHEMBL11429486 1.00 DGKA (0.86) DGKALPAR1LPAR4LPAR2LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012122144-A1 HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES WU NIAN (US) 2012-09-13 WO disclosed
US-20120232169-A1 HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES BIOZONE PHARMACEUTICALS, INC. (US) 2012-09-13 US disclosed
EP-2437756-A2 PURE PEG-LIPID CONJUGATES Wu, Nian (US) 2012-04-11 EP disclosed
US-20110040113-A1 Pure PEG-lipid conjugates WU NIAN 2011-02-17 US disclosed
WO-2010141069-A2 PURE PEG-LIPID CONJUGATES WU NIAN (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232169-A1 HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES LIPA, CETP, DGAT2 DGKA 30/4885LPAR1 513/4885LPAR4 360/4885
US-20110040113-A1 Pure PEG-lipid conjugates DGAT2, MGLL, DGAT1 DGKA 65/4885LPAR1 241/4885LPAR4 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.